A Double-blind Placebo Controlled Immunogenicity Study of Vacc-4x + Lenalidomide Versus Vacc-4x With an Initial Open-label Dose Escalation Assessment of Lenalidomide in HIV-1-infected Subjects on Antiretroviral Therapy (ART).

Trial Profile

A Double-blind Placebo Controlled Immunogenicity Study of Vacc-4x + Lenalidomide Versus Vacc-4x With an Initial Open-label Dose Escalation Assessment of Lenalidomide in HIV-1-infected Subjects on Antiretroviral Therapy (ART).

Completed
Phase of Trial: Phase I/II

Latest Information Update: 10 Mar 2017

At a glance

  • Drugs Vacc-4x (Primary) ; Lenalidomide
  • Indications HIV infections
  • Focus Adverse reactions; Pharmacodynamics
  • Acronyms IMID
  • Sponsors Bionor Pharma
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 17 Nov 2014 As per the media release, data of this trial will be submitted to a future major HIV medical conference.
    • 17 Nov 2014 As per the media release, the results of this trial will be discussed with FDA and European Medical Agency (EMA)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top